Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px
Document › Details

Arsanis, Inc.. (11/20/17). "Press Release: Arsanis Announces Closing of Initial Public Offering". Waltham, MA & Vienna.

Region Region United States (USA)
Organisations Organisation Arsanis Inc. (Nasdaq: ASNS)
  Group Arsanis (Group)
  Organisation 2 New Enterprise Associates (NEA)
Products Product ASN100 (Arsanis)
  Product 2 investment banking
Index terms Index term Arsanis–SEVERAL: investment, 201711 IPO $46m with 4m+600k shares common stock at $10/share at Nasdaq Global Market
  Index term 2 Arsanis–New Enterprise Associates: investment, 201711 private placement $20m with 2m shares common stock at $10/share
Persons Person Gray, Michael (Mike) (Arsanis 201702 CFO + CBO)
  Person 2 Gibbs, Krystle (Ten Bridge Communications 201703)
     


Arsanis, Inc. (NASDAQ:ASNS), a clinical-stage biopharmaceutical company focused on applying monoclonal antibody immunotherapies to address serious infectious diseases, today announced the closing of its initial public offering of 4,600,000 shares of its common stock at a public offering price of $10.00 per share, including 600,000 additional shares of common stock issued upon the exercise in full by the underwriters of their over-allotment option. The gross proceeds to Arsanis from the offering were $46.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares sold in the offering were offered by Arsanis. Arsanis’ shares began trading on The NASDAQ Global Market on November 16, 2017.

In addition, a fund affiliated with New Enterprise Associates purchased $20.0 million of Arsanis' common stock in a separate private placement concurrent with the completion of Arsanis' initial public offering at a price per share equal to the initial public offering price.

Citigroup, Cowen and Piper Jaffray & Co. acted as joint book-running managers for the public offering and as placement agents for the concurrent private placement.

A registration statement relating to the securities offered and sold in the initial public offering was filed with, and declared effective by, the Securities and Exchange Commission. Copies of the registration statement can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov.

This offering was made only by means of a prospectus. A copy of the final prospectus relating to the offering was filed with the Securities and Exchange Commission and may be obtained from Citigroup Global Markets Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (800) 831-9146; Cowen and Company, LLC, c/o Broadridge Financial Solutions, Attention: Prospectus Department, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (631) 274-2806; or Piper Jaffray & Co., Attention: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN 55402, by telephone at (800) 747-3924, or by email at prospectus@pjc.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state or jurisdiction.


About Arsanis

Arsanis, Inc. is a clinical-stage biopharmaceutical company focused on applying monoclonal antibody (mAb) immunotherapies to address serious infectious diseases. A deep understanding of the pathogenesis of infection, paired with access to some of the most advanced mAb discovery techniques and platforms available today, has positioned Arsanis to build and advance a pipeline of novel mAbs with multiple mechanisms of action and high potency against their intended targets. The company’s lead clinical program, ASN100, is aimed at serious Staphylococcus aureus infections and is being evaluated in a Phase 2 clinical trial for the prevention of S. aureus pneumonia in high-risk, mechanically ventilated patients. In addition to ASN100, its preclinical pipeline is comprised of mAbs targeting multiple serious bacterial and viral pathogens, including respiratory syncytial virus.

Arsanis is a U.S. company headquartered in Waltham, Massachusetts, with European research and preclinical development operations headquartered in Vienna, Austria (Arsanis Biosciences GmbH).


View source version on businesswire.com: http://www.businesswire.com/news/home/20171120006068/en/

Source: Arsanis, Inc.


Media Contact:
Ten Bridge Communications
Krystle Gibbs, 508-479-6358
krystle@tenbridgecommunications.com

or

Investor Contact:
Michael Gray, 781-819-5201
Chief Operating and Chief Financial Officer
mike.gray@arsanis.com

   
Record changed: 2018-03-18

Advertisement

Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 600x60px

More documents for Arsanis (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 600x60px




» top

Advertisements

Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 June Matchmaking 120x240px Picture [LSE] Life-Sciences-Europe.com – The Business Web Portal 120x600px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px Banner Fairtec GmbH Solutions for Smarter Business Events Exhibitions 120x120px Picture [iito] Twitter iitoLifeScience Life Sciences Mass Spec 120x120px Picture EBD Group ChinaBio Partnering Forum 2018 Suzhou CBPF April 120x180px Picture Berlin Partner HealthCapital Bionnale 2018 Germany June 120x240px